search
Back to results

Modified Valsalva Maneuver: A Realist Evaluation

Primary Purpose

Supraventricular Tachycardia

Status
Recruiting
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Implementation of Modified Valsalva maneuvre
Sponsored by
Ziekenhuis Oost-Limburg
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Supraventricular Tachycardia

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All adult patients that present to the emergency department
  • Only true SVT will be included.

Exclusion Criteria:

  • ECG more suggestive of atrial fibrillation or atrial flutter
  • Age < 18 years or > 70 years
  • Broad QRS, including known aberration
  • Known aneurysm (aortic, intracranial or elsewhere)
  • Known aortic stenosis
  • Known glaucoma
  • Hemodynamic instability requiring immediate electric cardioversion.
  • Patients that experience an SVT in the hospital but are never admitted to the emergency department (e.g., patients in the cardiac care unit), as the MVM protocol will be only implemented in the prehospital setting and ED.

Sites / Locations

  • Ziekenhuis Oost-Limburg
  • Ziekenhuis Oost-LimburgRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Implementing Modified Valsalva

Arm Description

Implementing Modified Valsalva

Outcomes

Primary Outcome Measures

Was Modified Valsalva maneuver used in this patient?
Yes/No. Was the patient's supraventricular tachycardie treated with Modified Valsalva or did they use a different treatment?

Secondary Outcome Measures

Was there a need for the use of medication or was the Modified Valsalva maneuver sufficient?
Length of stay in the ED
How long did the patient stayed in the emergency department?
Adverse events
Where there any adverse events correlated to the treatment used?
Hospital admission
Was there a need to admit the patient to the hospital?
Patient experience
Is it the first time you experienced this rhythm disturbance? To your knowledge, did they treat you by medication, or did they have you do a special maneuver? If they have made you do a special maneuver: Can you describe what maneuver they made you do? How many times did you do this maneuver? Was it successful? How did you experience this treatment? If they used medication for your rhythm disturbance: How many times did they give you this medication? How did you experience this treatment? If you were treated both by a maneuver and the medication, how did you experience one versus the other?
Staff experience
Do you know the recently implemented protocol of modified Valsalva maneuver in the treatment of an SVT? Did you use a non-pharmacological maneuver for termination of the SVT? Yes/No If you did not use a non-pharmacological maneuver, explain why. If you did use a non-pharmacological maneuver: What maneuver did you use? Can you describe it step by step? How many times did you apply this maneuver before it was successful or before you stopped trying it? Was it successful? If it was not successful, what was your next step? Did you use medication for the SVT? Yes/No What medication did you use? How many times did you have to give this medication? Was it successful? According to your experience, how do you rate the crowding of the ED on a Likert scale of 0-10?
Efficiency
Was the supraventricular tachycardia terminated after the used treatment (modified valsalva, valsalva, medication)?

Full Information

First Posted
July 5, 2022
Last Updated
August 29, 2023
Sponsor
Ziekenhuis Oost-Limburg
search

1. Study Identification

Unique Protocol Identification Number
NCT05466227
Brief Title
Modified Valsalva Maneuver: A Realist Evaluation
Official Title
Improving the Care Trajectory for Patients With Paroxysmal Supraventricular Tachycardia in the Emergency Department by Implementing the Modified Valsalva Maneuver: A Realist Evaluation
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2023 (Actual)
Primary Completion Date
December 30, 2023 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ziekenhuis Oost-Limburg

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Cardiac arrhythmia, specifically paroxysmal supraventricular tachycardia (SVT), accounts for a substantial proportion of emergency medical services resources utilization. Restoring a normal sinus rhythm (reconversion) should be done quickly and effectively. Reconversion requires increasing the atrioventricular node's refractoriness, which can be achieved by vagal maneuvers, pharmacological agents, or electrical cardioversion. The Valsalva Maneuver (VM) is a commonly used non-invasive reconversion method. It increases myocardial refractoriness by increasing intrathoracic pressure for a brief period, thus stimulating baroreceptor activity in the aortic arch and carotid bodies, resulting in increased parasympathetic (vagus nerve) tone. The effectiveness of conventional vagal maneuvers in terminating SVT, when correctly performed, shows a considerable variation ranging from 19.4% to 54.3%. To improve the effectiveness of the Valsalva Maneuver, the Modified Valsalva Maneuver (MVM) was introduced. While the standard VM is performed when the patient is in a sitting position (45°-90°), the modified VM involves having the patient sit up straight and perform a forced expiration for about 15 seconds, after which the patient is brought into a supine position with the legs raised (45°) for another 15 seconds. This modification should increase relaxation, phase venous return, and vagal stimulation. A recent meta-analysis demonstrated a significantly higher success rate for reconversion to sinus rhythm when using the MVM compared to the standard VM in patients with an SVT (Odds Ratio = 4.36; 95 percent c.i. 3.30 to 5.76; P < .001). More adverse events were reported in the MVM group, although this difference is not significant (Risk Ratio = 1.48; 95 percent c.i. 0.91 to 2.42; P = .11). The available evidence suggests that medication use was lower in the MVM group than in the standard VM group. However, medication use could not be generalized across the different studies. None of the included studies in this review showed a significant difference in length of stay in the emergency department (ED). Hence, the gain of implementing MVM is a higher rate of success with non-invasive reconversion methods. While the available evidence is highly suggestive of supporting the use of the MVM compared to the standard VM in the treatment of adult patients with SVT, implementation seems difficult. Current evaluations, such as the 'gold-standard' randomised controlled trial (RCT) design, rarely adequately or even explicitly address the context-specific drivers behind implementation outcomes and their relationship to the underlying programme theory, making it difficult to interpret their findings in light of other programmes in different settings. As a result, few evaluation strategies are widely accepted as appropriate. The net benefit of interventions and understanding how variable outcomes are achieved remains empirically uncertain. Therefore, it is essential to develop comprehensive, rigorous, and practical methods to evaluate people-centred quality improvement programmes, inform the selection of effective and efficient interventions, and facilitate improvement and scaling-up. In evaluating such complex interventions, the Medical Research Council (MRC) argues for the importance of process evaluation in conjunction with outcome evaluation to account for variability in implementation. The MRC's process evaluation framework guides evaluators to understand the implementation processes (what is implemented and how), mechanisms of intervention (how the delivery of the intervention produces change) and contextual factors that affect implementation and outcomes. Research question This study aimed to evaluate a quality improvement program to improve the non-invasive care for patients with paroxysmal supraventricular tachycardia in the emergency department.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Supraventricular Tachycardia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This is a mixed-methods study that uses realist evaluation as the overall conceptual framework to examine a quality improvement program to improve the care for patients with paroxysmal supraventricular tachycardia in the emergency department. A realist evaluation is methods-neutral, and the use of a mixed-methods approach employing a case note review, interviews, and focus groups with patients and staff will generate and analyse both qualitative and quantitative data to achieve the goal of the evaluation. Analysis of qualitative and quantitative data will be carried out using a convergent mixed-methods approach to ensure continuous triangulation of multiple data, which will provide a greater understanding of the findings in relation to policy and practice. Broadly, the evaluation could also be considered a process and outcome evaluation.
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Implementing Modified Valsalva
Arm Type
Experimental
Arm Description
Implementing Modified Valsalva
Intervention Type
Other
Intervention Name(s)
Implementation of Modified Valsalva maneuvre
Intervention Description
Modified Valsalva maneuvre: Patient is attached to 12-lead ECG monitoring The patient sits in an upright position and performs forced expiration for 15 seconds by blowing on a 10 mL syringe Patient's legs are elevated (45°) for 15 seconds Afterwards, the patient is placed back in an upright position If not efficient, this maneuver can be repeated up to two times
Primary Outcome Measure Information:
Title
Was Modified Valsalva maneuver used in this patient?
Description
Yes/No. Was the patient's supraventricular tachycardie treated with Modified Valsalva or did they use a different treatment?
Time Frame
Moment of treatment, no follow up. Up to 1 year since start of the study.
Secondary Outcome Measure Information:
Title
Was there a need for the use of medication or was the Modified Valsalva maneuver sufficient?
Time Frame
Moment of treatment, no follow up. Up to 1 year since start of the study.
Title
Length of stay in the ED
Description
How long did the patient stayed in the emergency department?
Time Frame
Moment of treatment, no follow up. Up to 1 year since start of the study.
Title
Adverse events
Description
Where there any adverse events correlated to the treatment used?
Time Frame
Moment of treatment, no follow up. Up to 1 year since start of the study.
Title
Hospital admission
Description
Was there a need to admit the patient to the hospital?
Time Frame
Moment of treatment, no follow up. Up to 1 year since start of the study.
Title
Patient experience
Description
Is it the first time you experienced this rhythm disturbance? To your knowledge, did they treat you by medication, or did they have you do a special maneuver? If they have made you do a special maneuver: Can you describe what maneuver they made you do? How many times did you do this maneuver? Was it successful? How did you experience this treatment? If they used medication for your rhythm disturbance: How many times did they give you this medication? How did you experience this treatment? If you were treated both by a maneuver and the medication, how did you experience one versus the other?
Time Frame
Moment of treatment, no follow up. Up to 1 year since start of the study.
Title
Staff experience
Description
Do you know the recently implemented protocol of modified Valsalva maneuver in the treatment of an SVT? Did you use a non-pharmacological maneuver for termination of the SVT? Yes/No If you did not use a non-pharmacological maneuver, explain why. If you did use a non-pharmacological maneuver: What maneuver did you use? Can you describe it step by step? How many times did you apply this maneuver before it was successful or before you stopped trying it? Was it successful? If it was not successful, what was your next step? Did you use medication for the SVT? Yes/No What medication did you use? How many times did you have to give this medication? Was it successful? According to your experience, how do you rate the crowding of the ED on a Likert scale of 0-10?
Time Frame
Moment of treatment, no follow up. Up to 1 year since start of the study.
Title
Efficiency
Description
Was the supraventricular tachycardia terminated after the used treatment (modified valsalva, valsalva, medication)?
Time Frame
Moment of treatment, no follow up. Up to 1 year since start of the study.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All adult patients that present to the emergency department Only true SVT will be included. Exclusion Criteria: ECG more suggestive of atrial fibrillation or atrial flutter Age < 18 years or > 70 years Broad QRS, including known aberration Known aneurysm (aortic, intracranial or elsewhere) Known aortic stenosis Known glaucoma Hemodynamic instability requiring immediate electric cardioversion. Patients that experience an SVT in the hospital but are never admitted to the emergency department (e.g., patients in the cardiac care unit), as the MVM protocol will be only implemented in the prehospital setting and ED.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hanne Gworek, MD
Phone
+32474521990
Email
hanne.gw@hotmail.com
Facility Information:
Facility Name
Ziekenhuis Oost-Limburg
City
Genk
ZIP/Postal Code
3600
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pieter Jan Van Asbroeck, MD
Phone
+32497139013
Email
pjvanasbroeck@gmail.com
First Name & Middle Initial & Last Name & Degree
Hanne Gworek, MD
Phone
+32474521990
Email
hanne.gw@hotmail.com
First Name & Middle Initial & Last Name & Degree
Ine Bollen, MD
First Name & Middle Initial & Last Name & Degree
Pieter Jan Van Asbroeck, MD
First Name & Middle Initial & Last Name & Degree
Hanne Gworek, MD
Facility Name
Ziekenhuis Oost-Limburg
City
Genk
ZIP/Postal Code
3600
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ziekenhuis Oost-Limburg

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Modified Valsalva Maneuver: A Realist Evaluation

We'll reach out to this number within 24 hrs